Context Therapeutics Inc. (CNTX)
(Delayed Data from NSDQ)
$2.48 USD
-0.02 (-0.80%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.48 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for Context Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 25 | 15 | 11 | 3 | 0 |
Income After Depreciation & Amortization | -25 | -15 | -11 | -3 | 0 |
Non-Operating Income | 1 | 0 | 0 | 10 | NA |
Interest Expense | 0 | -1 | 0 | 1 | NA |
Pretax Income | -24 | -15 | -10 | 7 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -24 | -15 | -10 | 7 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -24 | -15 | -10 | 7 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -25 | -15 | -11 | -3 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -25 | -15 | -11 | -3 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 15.97 | 15.97 | 2.83 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.50 | -0.93 | -3.69 | NA | NA |
Diluted Net EPS (GAAP) | -1.50 | -0.93 | -3.69 | NA | NA |
Fiscal Year end for Context Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 3.08 | 3.82 | 6.93 | 6.19 | 5.29 |
Income After SG&A, R&D, and Dept/Amort Expenses | -3.08 | -3.82 | -6.93 | -6.19 | -5.29 |
Non-Operating Income | 0.83 | 0.16 | 0.16 | 0.31 | 0.28 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -2.25 | -3.67 | -6.77 | -5.87 | -5.01 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.25 | -3.67 | -6.77 | -5.87 | -5.01 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.25 | -3.67 | -6.77 | -5.87 | -5.01 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 54.96 | 15.97 | 16.12 | 15.97 | 15.97 |
Diluted EPS Before Non-Recurring Items | -0.04 | -0.23 | -0.42 | -0.37 | -0.31 |
Diluted Net EPS (GAAP) | -0.04 | -0.23 | -0.42 | -0.37 | -0.31 |